COSTA MESA, Calif., Oct. 31 /PRNewswire-FirstCall/ -- CNS Response, Inc. announced today that Henry T. Harbin, MD has been appointed to the Company’s Board of Directors. A psychiatrist with over 30- years experience in the behavioral health field, Dr. Harbin has served as the CEO of two national behavioral health care companies and has held numerous senior positions in both the public and private mental health sectors.
Len Brandt, chairman and CEO of CNS Response, commented, “CNS Response is extremely fortunate to add Dr. Harbin’s experience and acumen to our Board of Directors. I simply don’t know anyone who has been more at the forefront of advancing behavioral healthcare management these past twenty-five years. Beyond that, Dr. Harbin is a creative force who has already influenced our thinking on initiatives to accelerate the impact that the objective guidance of rEEG(SM) can make for patients and payers alike.”
Among his past accomplishments, Dr. Harbin served as Commissioner of the President’s New Freedom Commission on Mental Health from 2002 to 2003, chairing the subcommittee for the Interface between Mental Health and General Medicine. In addition to his Federal government experience, Dr. Harbin also spent 10 years in the public mental health system in Maryland, serving as Director of the State Mental Health Authority for three of those years.
As the chairman, CEO and President of Magellan Health Services, the country’s leading behavioral managed care organization, Dr. Harbin led a company with approximately 6,500 employees and revenues of $1.7 billion. During his tenure from 1998 to 2004, Magellan managed the mental health and substance abuse benefits of approximately 70 million Americans including persons who were insured by private employers, Medicaid and Medicare. Prior to Magellan, Dr. Harbin worked for Green Spring Health Services, Inc., one of the largest managed behavioral health organizations in the country. Dr. Harbin held several executive positions at the company, including five years as its president and CEO.
Among his achievements in research, Dr. Harbin was a principal investigator and project director for multiple studies at the University of Maryland’s Institute of Psychiatry and Human Behavior, and has served as a reviewer for the American Journal of Psychiatry, Journal of Nervous and Mental Disease, and Hospital & Community Psychiatry. Dr. Harbin has also been published in over 10 peer-reviewed articles.
Dave Jones, Managing Partner of Sail Venture Capital and a member of the CNS Response Board of Directors, remarked, “The experience and enthusiasm of the people becoming associated with CNS Response, including Dr. Henry Harbin, our new President, George Carpenter, the new Chief Medical Officer, Daniel Hoffman, MD, and others joining Len, combined with the core team, allows this company to capitalize on its extraordinary vision and opportunity.”
About CNS Response
CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports (“rEEG(SM) Reports”) that specifically guide physicians to treatment strategies based on the patient’s own physiology.
rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
sephraim@theruthgroup.comjmccargo@theruthgroup.comjrando@theruthgroup.com
CONTACT: Investor Relations: Sara Ephraim, +1-646-536-7002,
sephraim@theruthgroup.com, or Media: Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, all of The Ruth Group, for CNS Response, Inc.
Web site: http://www.cnsresponse.com/
